Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract ...

Escalating antimicrobial resistance is a global threat, emphasizing the need to explore alternative treatment options. Hence, we aimed to explore the ...

NHS hospitals have seen a 30 per cent spike in cases of antibiotic-resistant bacteria - which can be fatal if it enters the ...

A major treatment gap for life-threatening carbapenem-resistant Gram-negative bacterial infections has been revealed across ...

Hospitals in the UK have seen a 30% spike in cases of dangerous superbugs resistant to antibiotics which has been triggered ...

Conclusion. Doripenem is an injectable carbapenem antibiotic with a spectrum of activity comparable to that of imipenem and meropenem. Its safety is similar to that of other carbapenems.

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be comple ...

The FDA delivered a blow to Spero's hopes of bringing the carbapenem to market in a complete response letter (CRL) delivered this week, which said another trial would be required to support approval.

Tebipenem is the first oral drug in the carbapenem antibiotic class to reach late-stage development and, despite the desperate need for new antimicrobials, was turned down in June by the FDA ...

Purpose: The stability of meropenem in i.v. solutions stored in polyvinyl chloride (PVC) bags and an elastomeric infusion device at concentrations commonly used in home care was studied.

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...